clenbuterol has been researched along with Cardiomegaly in 7 studies
Clenbuterol: A substituted phenylaminoethanol that has beta-2 adrenomimetic properties at very low doses. It is used as a bronchodilator in asthma.
clenbuterol : A substituted aniline that is 2,6-dichloroaniline in which the hydrogen at position 4 has been replaced by a 2-(tert-butylamino)-1-hydroxyethyl group.
Cardiomegaly: Enlargement of the HEART, usually indicated by a cardiothoracic ratio above 0.50. Heart enlargement may involve the right, the left, or both HEART VENTRICLES or HEART ATRIA. Cardiomegaly is a nonspecific symptom seen in patients with chronic systolic heart failure (HEART FAILURE) or several forms of CARDIOMYOPATHIES.
| Excerpt | Relevance | Reference |
|---|---|---|
| " The beta 2-adrenoceptor agonist clenbuterol was used to investigate its potential to selectively induce skeletal muscle hypertrophy, particularly the latissimus dorsi muscle (LDM), independent of adverse effects on cardiac muscle." | 7.69 | Clenbuterol induces hypertrophy of the latissimus dorsi muscle and heart in the rat with molecular and phenotypic changes. ( Boheler, KR; Petrou, M; Wynne, DG; Yacoub, MH, 1995) |
| " When rats were fed with clenbuterol for 7 days skeletal muscle mass increased by 21% in the tonic soleus and phasic plantaris muscles and a 16% hypertrophy of the heart was also induced." | 7.68 | Effects of the cyclo-oxygenase inhibitor, fenbufen, on clenbuterol-induced hypertrophy of cardiac and skeletal muscle of rats. ( Bain, P; Delday, MI; Maltin, CA; McMillan, DN; Noble, BS; Palmer, RM, 1990) |
| " We have studied the induction of cardiac hypertrophy after treatment with clenbuterol and the role of polyamines in this effect." | 3.70 | Polyamine-mediated heart hypertrophy induced by clenbuterol in the mouse. ( Balaña-Fouce, R; Cubría, JC; Ordóñez, C; Ordóñez, D; Reguera, R, 1998) |
| " The beta 2-adrenoceptor agonist clenbuterol was used to investigate its potential to selectively induce skeletal muscle hypertrophy, particularly the latissimus dorsi muscle (LDM), independent of adverse effects on cardiac muscle." | 3.69 | Clenbuterol induces hypertrophy of the latissimus dorsi muscle and heart in the rat with molecular and phenotypic changes. ( Boheler, KR; Petrou, M; Wynne, DG; Yacoub, MH, 1995) |
| " When rats were fed with clenbuterol for 7 days skeletal muscle mass increased by 21% in the tonic soleus and phasic plantaris muscles and a 16% hypertrophy of the heart was also induced." | 3.68 | Effects of the cyclo-oxygenase inhibitor, fenbufen, on clenbuterol-induced hypertrophy of cardiac and skeletal muscle of rats. ( Bain, P; Delday, MI; Maltin, CA; McMillan, DN; Noble, BS; Palmer, RM, 1990) |
| "Clenbuterol treatment resulted in increased cell size of cardiac myocytes with increased protein accumulation and myofibrillar organisation characteristic of hypertrophic growth." | 1.36 | Clenbuterol induces cardiac myocyte hypertrophy via paracrine signalling and fibroblast-derived IGF-1. ( Barton, PJ; Bhavsar, PK; Brand, NJ; Cullen, ME; Felkin, LE; Luther, PK; Yacoub, MH, 2010) |
| "Clenbuterol treatment induced rapid development of cardiac hypertrophy with increased muscle mass at day 1 and elevated heart rate and QT interval throughout the 28-day period." | 1.35 | A gene expression profile of the myocardial response to clenbuterol. ( Barton, PJ; Felkin, LE; Lara-Pezzi, E; Smolenski, RT; Soppa, GK; Terracciano, CM; Yacoub, MH, 2009) |
| "Appropriate cardiac hypertrophy (CH) is necessary in several clinical settings, such as pulmonary artery banding in the two-stage arterial switch operation for transposition of the great arteries." | 1.30 | Pharmacological modulation of pressure-overload cardiac hypertrophy: changes in ventricular function, extracellular matrix, and gene expression. ( Boheler, KR; Petrou, M; Wong, K; Yacoub, MH, 1997) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (71.43) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lara-Pezzi, E | 1 |
| Terracciano, CM | 1 |
| Soppa, GK | 1 |
| Smolenski, RT | 1 |
| Felkin, LE | 2 |
| Yacoub, MH | 4 |
| Barton, PJ | 2 |
| Bhavsar, PK | 1 |
| Brand, NJ | 1 |
| Luther, PK | 1 |
| Cullen, ME | 1 |
| Petrou, M | 2 |
| Wynne, DG | 1 |
| Boheler, KR | 2 |
| Wong, K | 1 |
| Cubría, JC | 1 |
| Reguera, R | 1 |
| Balaña-Fouce, R | 1 |
| Ordóñez, C | 1 |
| Ordóñez, D | 1 |
| Murphy, RJ | 1 |
| Béliveau, L | 1 |
| Gardiner, PF | 1 |
| Calderone, A | 1 |
| Palmer, RM | 1 |
| Delday, MI | 1 |
| McMillan, DN | 1 |
| Noble, BS | 1 |
| Bain, P | 1 |
| Maltin, CA | 1 |
7 other studies available for clenbuterol and Cardiomegaly
| Article | Year |
|---|---|
A gene expression profile of the myocardial response to clenbuterol.
Topics: Adrenergic beta-Agonists; Animals; Cardiomegaly; Cell Proliferation; Cells, Cultured; Clenbuterol; E | 2009 |
Clenbuterol induces cardiac myocyte hypertrophy via paracrine signalling and fibroblast-derived IGF-1.
Topics: Actins; Adrenergic beta-2 Receptor Agonists; Animals; Animals, Newborn; Atrial Natriuretic Factor; B | 2010 |
Clenbuterol induces hypertrophy of the latissimus dorsi muscle and heart in the rat with molecular and phenotypic changes.
Topics: Adipose Tissue; Animals; Base Sequence; Body Weight; Cardiomegaly; Clenbuterol; Forelimb; Hypertroph | 1995 |
Pharmacological modulation of pressure-overload cardiac hypertrophy: changes in ventricular function, extracellular matrix, and gene expression.
Topics: Analysis of Variance; Animals; Blood Pressure; Calcium-Transporting ATPases; Cardiomegaly; Clenbuter | 1997 |
Polyamine-mediated heart hypertrophy induced by clenbuterol in the mouse.
Topics: Adrenergic beta-Agonists; Animals; Body Weight; Cardiomegaly; Clenbuterol; Heart; Male; Mice; Mice, | 1998 |
Nifedipine does not impede clenbuterol-stimulated muscle hypertrophy.
Topics: Adrenergic beta-Agonists; Animals; Blood Pressure; Body Weight; Calcium; Calcium Channels; Calcium C | 1999 |
Effects of the cyclo-oxygenase inhibitor, fenbufen, on clenbuterol-induced hypertrophy of cardiac and skeletal muscle of rats.
Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Cardiomegaly; Clenbuterol; Cyclooxygenase Inhibito | 1990 |